Physician profile
Dale E Edlin
NPI 1740250117
$5,508.63
in general payments reported to CMS, 2019-2025
28 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,080 · 2020: $562 · 2021: $1,463 · 2022: $1,520 · 2023: $792 · 2024: $91.17.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $883.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $883.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,010.97 | 2019-2023 | Brilinta, Farxiga |
| Abbott Laboratories | $758.13 | 2021-2024 | Cardiomems, Aveir |
| Novartis Pharmaceuticals Corporation | $577.64 | 2019-2023 | |
| Janssen Pharmaceuticals, INC | $415.35 | 2019-2022 | |
| Pfizer INC. | $399.09 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $394.00 | 2021-2023 | Verquvo |
| Amgen INC. | $344.10 | 2019-2023 | Repatha |
| E.R. Squibb & Sons, L.L.C. | $310.83 | 2019-2023 | Camzyos |
| Amarin Pharma, INC. | $271.06 | 2019-2022 | |
| Cvrx, INC. | $145.13 | 2023 | Barostim Neo System |
| Boehringer Ingelheim Pharmaceuticals, INC. | $128.24 | 2019-2023 | Jardiance |
| Astellas Pharma US INC | $99.00 | 2019 | |
| Esperion Therapeutics, INC. | $96.31 | 2020-2023 | Nexletol |
| Sanofi-Aventis U.S. LLC | $94.68 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $91.89 | 2019-2021 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $68.07 | 2019-2021 | |
| W. L. Gore & Associates, INC. | $53.76 | 2022 | |
| Abiomed | $41.82 | 2024 | Impella |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $37.51 | 2022-2023 | Lifevest |
| Arbor Pharmaceuticals, INC. | $29.29 | 2020-2021 | |
| Atricure, INC. | $25.17 | 2024 | |
| Irhythm Technologies, INC. | $22.94 | 2020 | |
| Boston Scientific Corporation | $18.79 | 2019 | |
| Potrero Medical, INC. | $17.12 | 2023 | |
| Tactile Systems Technology INC | $16.96 | 2020 | |
| Akcea Therapeutics, INC. | $14.32 | 2020 | |
| Gilead Sciences, INC. | $13.26 | 2019 | |
| Lexicon Pharmaceuticals, INC. | $13.20 | 2023 | Inpefa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dale Edlin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.